188 related articles for article (PubMed ID: 752014)
1. Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome.
Dalakos TG; Elias AN; Anderson GH; Streeten DH; Schroeder ET
J Clin Endocrinol Metab; 1978 Jan; 46(1):114-8. PubMed ID: 752014
[TBL] [Abstract][Full Text] [Related]
2. The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome.
Vetter W; Vetter H; Beckerhoff R; Redlich B; Cottier P; Siegenthaler W
Klin Wochenschr; 1976 Jul; 54(14):661-3. PubMed ID: 979066
[TBL] [Abstract][Full Text] [Related]
3. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome.
Saruta T; Suzuki H; Handa M; Igarashi Y; Kondo K; Senba S
J Clin Endocrinol Metab; 1986 Feb; 62(2):275-9. PubMed ID: 3510223
[TBL] [Abstract][Full Text] [Related]
4. The use of saralasin in the recognition of angiotensinogenic hypertension.
Streeten DH; Dalakos TG; Anderson GH
Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
[TBL] [Abstract][Full Text] [Related]
5. Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension.
Dluhy RG; Bavli SZ; Leung FK; Solomon HS; Moore TJ; Hollenberg NK; Williams GH
J Clin Invest; 1979 Nov; 64(5):1270-6. PubMed ID: 500810
[TBL] [Abstract][Full Text] [Related]
6. Pathogenetic aspects of hypertension in Cushing's syndrome.
Tenschert W; Baumgart P; Greminger P; Vetter W; Vetter H
Cardiology; 1985; 72 Suppl 1():84-90. PubMed ID: 3902234
[TBL] [Abstract][Full Text] [Related]
7. The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.
Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
Aust N Z J Med; 1976 Aug; 6(3 Suppl):48-52. PubMed ID: 1071403
[TBL] [Abstract][Full Text] [Related]
8. Plasma renin activity and urinary aldosterone in Cushing's syndrome.
Mantero F; Armanini D; Boscaro M
Horm Metab Res; 1978 Jan; 10(1):65-71. PubMed ID: 204567
[TBL] [Abstract][Full Text] [Related]
9. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
[TBL] [Abstract][Full Text] [Related]
10. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma.
Yasuda G; Shionoiri H; Umemura S; Takasaki I; Ishii M
Eur J Endocrinol; 1994 Dec; 131(6):582-8. PubMed ID: 7804440
[TBL] [Abstract][Full Text] [Related]
11. The effect of an angiotensin antagonist (saralasin) on arterial pressure and plasma aldosterone in hemodialysis-resistant hypertensive patients.
Mimran A; Shaldon S; Barjon P; Mion C
Clin Nephrol; 1978 Feb; 9(2):63-7. PubMed ID: 639368
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin II blockade by saralasin in normal man.
Noth RH; Tan SY; Mulrow PJ
J Clin Endocrinol Metab; 1977 Jul; 45(1):10-5. PubMed ID: 874056
[TBL] [Abstract][Full Text] [Related]
13. [Saralasin in subjects with low renin arterial hypertension].
Frisina N; Buemi M; Lasco A; Macrà I; Ciraolo O; Nicita Mauro V; Costa G
Boll Soc Ital Biol Sper; 1980 Jul; 56(13):1367-73. PubMed ID: 7004464
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system and plasma aldosterone in Cushing's syndrome.
Baba T; Aoyagi K; Murabayashi S; Sasaki K; Nigawara K; Takebe K
Endocrinol Jpn; 1983 Dec; 30(6):715-21. PubMed ID: 6327249
[TBL] [Abstract][Full Text] [Related]
15. Changes of blood pressure, plasma renin activity and plasma aldosterone concentration following the infusion of Sar1-Ile8-angiotensin II in hypertensive, fluid and electrolyte disorders.
Yamamoto T; Doi K; Ogihara T; Ichihara K; Hata T; Kumahara Y
Prog Biochem Pharmacol; 1976; 12():174-89. PubMed ID: 1019163
[TBL] [Abstract][Full Text] [Related]
16. Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly.
Moore TJ; Thein-Wai W; Dluhy RG; Dawson-Hughes BF; Hollenberg NK; Williams GH
J Clin Endocrinol Metab; 1980 Aug; 51(2):215-22. PubMed ID: 6995474
[No Abstract] [Full Text] [Related]
17. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;
Streeten DH; Anderson GH; Freiberg JM; Dalakos TG
N Engl J Med; 1975 Mar; 292(13):657-62. PubMed ID: 235090
[TBL] [Abstract][Full Text] [Related]
18. Saralasin bolus test. Rapid screening procedure for renin-mediated hypertension.
Marks LS; Maxwell MH; Kaufman JJ
Lancet; 1975 Oct; 2(7939):784-7. PubMed ID: 78152
[TBL] [Abstract][Full Text] [Related]
19. [Variations of the renin aldosterone system in Cushing's disease (author's transl)].
Bricaire H; Thibonnier M; Hautecouverture M; Corvol P; Luton JP
Nouv Presse Med; 1980 Mar; 9(14):1007-9. PubMed ID: 6988802
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and aldosterone in hypertension.
Fagard R; Lijnen P; Amery A; Reybrouck T
Contrib Nephrol; 1978; 11():175-8. PubMed ID: 699588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
